Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR8392884

— · cohortA1

9cbf894e-16ca-5e15-a9e1-b9148fdaa095

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
  • COAGULATION+0.490
  • TNFA_SIGNALING_VIA_NFKB+0.490
  • APICAL_JUNCTION+0.440
  • ANGIOGENESIS+0.420
  • IL6_JAK_STAT3_SIGNALING+0.400
  • INFLAMMATORY_RESPONSE+0.400
  • COMPLEMENT+0.390
  • TGF_BETA_SIGNALING+0.390
  • HYPOXIA+0.370

Top 10 suppressed

  • E2F_TARGETS-0.620
  • G2M_CHECKPOINT-0.560
  • MYC_TARGETS_V1-0.560
  • MYC_TARGETS_V2-0.540
  • UNFOLDED_PROTEIN_RESPONSE-0.350
  • MTORC1_SIGNALING-0.300
  • OXIDATIVE_PHOSPHORYLATION-0.290
  • SPERMATOGENESIS-0.290
  • DNA_REPAIR-0.220
  • PROTEIN_SECRETION-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1797296
lung-landscapes@6
—cohortMD20.943
2BS_ZV9Z3SY6
brain-umap@2
pilocytic astrocytoma—0.939
3MDT-AP-0384
medullo-epn-umap@date-based
MedMedulloblastoma0.934
445b4921e-fce7-41f8-bb63-ed98343ceec8
colon-landscapes@1
——0.933
5TCGA-55-7281-01A-11R-2039-07
lung-landscapes@6
—cohortA10.927
6SRR8518124
breast-umap@18
—D0.925
7SAMN03290935
melanoma-umap@29
——0.924
8C3L-02552
lung-landscapes@6
—cohortSQ10.924
9C3N-00545
lung-landscapes@6
—cohortA10.922
10ERR2208941
melanoma-umap@29
——0.922

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.540Inavolisib— uncovered
COAGULATION0.490Binimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.490Inavolisib— uncovered
APICAL_JUNCTION0.440Inavolisib— uncovered
ANGIOGENESIS0.420Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.400Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
COMPLEMENT0.390Inavolisib— uncovered
TGF_BETA_SIGNALING0.390Inavolisib— uncovered
HYPOXIA0.370Idelalisib— uncovered
KRAS_SIGNALING_UP0.370Inavolisib— uncovered
MYOGENESIS0.370Inavolisib— uncovered
NOTCH_SIGNALING0.360Inavolisib— uncovered
APOPTOSIS0.350Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.310Inavolisib— uncovered
P53_PATHWAY0.290Idelalisib— uncovered
ALLOGRAFT_REJECTION0.260Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.260Inavolisib— uncovered
HEDGEHOG_SIGNALING0.230Inavolisib— uncovered
IL2_STAT5_SIGNALING0.230Idelalisib— uncovered